Vol 45, No 1 (2007)
Original paper
Submitted: 2011-12-19
Published online: 2007-03-24
Thrombin activatable fibrinolysis inhibitor (TAFI) in cord blood.
Waldemar Uszyński, Mieczysław Uszyński, Ewa Zekanowska, Krzysztof Góralczyk
Folia Histochem Cytobiol 2007;45(1):33-36.
Vol 45, No 1 (2007)
ORIGINAL PAPERS
Submitted: 2011-12-19
Published online: 2007-03-24
Abstract
Thrombin activatable fibrinolysis inhibitor (TAFI) is a plasma zymogene (procarboxypeptidase B) which can decrease fibrinolysis and thus act as a haemostatic factor. TAFI is now extensively studied in many complications as well as in physiological and complicated pregnancy. The question we posed in the present study was whether TAFI antigen is present in cord blood plasma. The study group consisted of 38 parturient women, 26 primiparous and 12 multiparous with normal course of pregnancy and delivery. The cord blood was sampled from the cord vein, and the mother's blood from the antecubital vein. 3.2% sodium citrate was used as an anticoagulant. TAFIa/ai antigen was measured by ELISA method. TAFIa/ai antigen was identified in all samples of cord blood plasma. Its level was 91.50 ng/ml (range: 71.76 - 160.77 ng/ml) vs. 55.46 ng/ml (range: 39.77 - 68.54 ng/ml ) in the mother's blood, which means that the level of TAFIa/ai antigen was significantly higher in fetal blood than in maternal blood (p<0.00001). TAFIa/ai antigen is an integral component of cord blood plasma. The concentration of TAFIa/ai antigen is about two times higher in fetal blood than in maternal blood.
Abstract
Thrombin activatable fibrinolysis inhibitor (TAFI) is a plasma zymogene (procarboxypeptidase B) which can decrease fibrinolysis and thus act as a haemostatic factor. TAFI is now extensively studied in many complications as well as in physiological and complicated pregnancy. The question we posed in the present study was whether TAFI antigen is present in cord blood plasma. The study group consisted of 38 parturient women, 26 primiparous and 12 multiparous with normal course of pregnancy and delivery. The cord blood was sampled from the cord vein, and the mother's blood from the antecubital vein. 3.2% sodium citrate was used as an anticoagulant. TAFIa/ai antigen was measured by ELISA method. TAFIa/ai antigen was identified in all samples of cord blood plasma. Its level was 91.50 ng/ml (range: 71.76 - 160.77 ng/ml) vs. 55.46 ng/ml (range: 39.77 - 68.54 ng/ml ) in the mother's blood, which means that the level of TAFIa/ai antigen was significantly higher in fetal blood than in maternal blood (p<0.00001). TAFIa/ai antigen is an integral component of cord blood plasma. The concentration of TAFIa/ai antigen is about two times higher in fetal blood than in maternal blood.
Title
Thrombin activatable fibrinolysis inhibitor (TAFI) in cord blood.
Journal
Folia Histochemica et Cytobiologica
Issue
Vol 45, No 1 (2007)
Article type
Original paper
Pages
33-36
Published online
2007-03-24
Page views
1282
Article views/downloads
1477
Bibliographic record
Folia Histochem Cytobiol 2007;45(1):33-36.
Authors
Waldemar Uszyński
Mieczysław Uszyński
Ewa Zekanowska
Krzysztof Góralczyk
About this article